Fig. 1From: Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home settingProportion of successful home administrations in a overall population and b prespecified subgroups. Q2W biweekly (140 mg), QM monthly (420 mg), T-1 THOMAS-1, T-2 THOMAS-2Back to article page